The pulmonary residence time of free and liposome-encapsulated tobramycin was studied with uninfected rats and rats infected with Pseudomonas aeruginosa. Chronic infection in lungs was established by intratracheal administration of 108 CFU of P. aeruginosa PA 508 prepared in agar beads. After 3 days, a single dose (300 ,ug) of free or liposome-encapsulated tobramycin was given intratracheally to both infected and uninfected rats. At various time intervals (0.25 to 16 h) after drug instillations, the remaining tobramycin was evaluated in blood, lungs, and kidneys by a microbiological assay. Intratracheal instillation of liposome-encapsulated tobramycin resulted in high and sustained levels of tobramycin in lungs of uninfected and infected rats over the 16-h period studied; however, the tobramycin levels were two times higher in uninfected rats. There was no tobramycin detected in the blood or kidneys from these animals. In contrast, the intratracheally instilled free tobramycin was cleared within 3 and 1 h from the lungs of uninfected and infected animals, respectively. These data suggest that the encapsulation of tobramycin in liposomes can result in a significant increase of its residence time within lungs. This study also shows that pulmonary infection was associated with a lowering of tobramycin levels in lungs.
Chronic lung infection due to Pseudomonas aeruginosa is the major cause of morbidity and mortality in patients with cystic fibrosis (CF) (20, 44, 45) . P. aeruginosa is an adaptable opportunistic microorganism that has the capacity to respond to a variety of environmental changes and has usually high intrinsic resistance to numerous antimicrobial drugs (17, 19) . This inherent bacterial resistance seems to be associated with the low permeability of the outer membrane of the cell to some antimicrobial agents (4, 17, 46) . Efficient therapy targeted against P. aeruginosa remains difficult and controversial (8, 29) . Usually, an aminoglycoside or beta-lactam antibiotic alone or both in combination are used as standard therapy for CF patients colonized with this organism (28, 38) . These antibacterial agents require frequent high-dose parenteral administration in order to achieve therapeutically effective concentrations in serum, particularly against old biofilm cells formed by the mucoid phenotype of this organism (25, 39) . However, prolonged or repeated treatment has been associated with gradually decreasing susceptibility of P. aeruginosa (33) and with accelerated clearance of antibiotics in these patients (21) .
A prerequisite for the efficacy of these antibiotics in lung infections is that these agents must pass into the bronchial tree to reach the infected foci in order to achieve an elevated and persistent bioactive concentration in the sputum (2) .
Local administration of antibiotics into the bronchial tree has been shown to be an interesting approach in the management of human lower respiratory tract infections due to bacterial, fungal, viral, and protozoan agents (41 343-5701. significantly better bacteriological eradication than placebo in a double-blind study of pneumonia in humans due to gramnegative organisms (12) . After endotracheal instillation and aerosolization of free tobramycin, Valcke and Pauwels (43) observed a sustained concentration of the antibiotic in normal rat lungs, concomitant with minimal systemic absorption. It was also demonstrated that nonpenetrable compounds can be introduced into the cells of P. aeruginosa by the use of liposomes (37) , thereby facilitating the diffusion of the drug through bacterial external envelopes to its site of action. The main reasons for the use of liposomes include (i) sustained drug release, (ii) reduced dose requirement and/or possibility of administering a larger dose with reduced toxicity, and (iii) increased sensitivity of P. aeruginosa to the liposome-encapsulated antibiotic as previously reported (24, 31) .
To our current knowledge, the persistence of liposomeencapsulated tobramycin instilled into animal lungs has not been assessed yet. The current study was undertaken to (i) determine the pulmonary residence of liposome-encapsulated tobramycin in experimental rat pseudomonal pneumonia and to (ii) investigate the effect of this infection on the concentration of antibiotics within lungs.
PULMONARY RETENTION OF LIPOSOMAL TOBRAMYCIN 1091 with P. aeruginosa PA 508 in agar beads. Another group of 65 rats received the same volume of sterile agar beads and served as uninfected controls. Bacteria were coated in agar beads as previously described (14) . The bacterial count was ascertained by 10-fold serial dilutions in phosphate-buffered saline (PBS) on Proteose Peptone agar plates as described below. Before infection, the rats were anesthetized with a mixture of 70 mg of ketamine hydrochloride per kg of body weight (Rogar/STB Inc., Montreal, Quebec, Canada) and 7 mg of xylazine per kg (BAYVET Division, Chemagro Limited, Etobicoke, Ontario, Canada) by intramuscular injection. Anesthetized rats were placed in the supine position, and the upper jaw was attached to the operating table by a rubber band brought over the incisor teeth. A laryngoscope with a modified (narrowed laterally near its extremities) Wisconsin pediatric blade no. 0 was used to visualize the larynx, and a catheter with a polished stylet was inserted between the vocal cords and pushed gently forward into the trachea (20-mm depth) . The stylet and the laryngoscope were then withdrawn, and intubation was confirmed by the formation of water condensation on a cold mirror with each breath of the rat. A 250-pul calibrated Hamilton syringe was used to introduce, at the bifurcation of the trachea, 108 CFU of P. aeruginosa PA 508 (0.1 ml) prepared in agar beads. Inoculation was followed by a bolus of air to disperse the beads into the lungs. Three days after the inoculation of agar beads, uninfected and infected animals received one dose of either 0.1 ml of free tobramycin (300 Rg) or 0.1 ml of liposome-encapsulated tobramycin (300 ,ug) by intratracheal instillation (18-gauge, 20-mm catheter) by the same methodology as described for infection. Following instillation, the animals' heads were immediately elevated approximately 300 above the horizontal plane and maintained in that position until they recovered from the anesthesia. Ten uninfected and infected control animals were left without antibiotic treatment. Lung bacterial counts were performed in 30% of infected animals to control the persistence of the chronic pulmonary infection. Serial 10-fold dilutions of the homogenates in cold PBS were made, and 0.1 ml of each dilution was pipetted and spread on cetrimide agar (BBL Microbiology Systems, Cockeysville, Md.). CFU were counted after 24-h incubations at 37°C under 5% CO2. Counts were expressed in log CFU per pair of lungs.
Preparation of liposomes. Liposomes were prepared with a 10:1 molar ratio of disteroyl phosphatidylcholine and dimyristoyl phosphatidyl-glycerol (Avanti Polar Lipids Inc., Birmingham, Ala.) by a reverse-phase evaporation procedure previously described (24) . Briefly, appropriate amounts of lipid mixture were dissolved in chloroform in a round-bottom flask and dried to a lipid film by rotoevaporation (Buchi Rotavapor-KRvr 65\45) at 65°C under vacuum (Buchi 168-Vacuum\Distillation controller). The lipids were then redissolved in tobramycin (Eli Lilly, Toronto, Ontario, Canada) and lyophilized in ampoules. Ampoules were kept at -70°C until use. After rehydration with the antibiotic, liposomes were filtered through an extruder (Lipex Biomembranes Inc., Vancouver, British Columbia, Canada) charged with a polycarbonate membrane (0.4 ,um). Control liposomes were prepared similarly, but PBS was used instead of the antibiotic.
The procedure for the determination of tobramycin in liposomes was based on derivatization of the tobramycin with 1-fluoro-2,4-dinitrobenzene. Liposome samples for high-performance liquid chromatography (HPLC) analysis were treated as follows: 100 pl of liposomes was added to 5 ml of methanol (MeOH) at 65°C and vortexed for 1 min; 490 RI of PBS was then added and vortexed for 1 min after centrifugation at 4,000 x g for 20 min, at 4°C. A total of 100 RI of the supematant was diluted with 0.9 ml of PBS, and 100 pl was transferred in an ampoule containing 54 [lI of 1-fluoro-2,4-dinitrobenzene prepared in MeOH (180 g/liter), 40 [lI of 0.1 M borate buffer (pH 9.3), and 400,u of MeOH. Ampoules were sealed, vortexed, and heated for 30 min at 80°C and then cooled at room temperature.
For the standards, tobramycin solutions were prepared in PBS with known amounts of tobramycin and processed as described above for encapsulated tobramycin.
HPLC with UV detection as previously described (5-7) was used. The HPLC system was composed of a pump and a system controller (Varian model 5000), a simple loop injector (Reodyne 7125), a UV spectrophotometric detector (Varian 2550), and a recorder (Spectra-Physics SP 4290). The separation was carried out on a Nova-Pak C18 cartridge column (inside diameter, 10 by 0.8 mm; particle size, 4 ,um [Waters Chromatography]). The mobile phase was acetonitrile-MeOH-potassium phosphate buffer (10 mM) (65:10:25, vol/vol [pH 7.2]), and the flow rate was 1.3 ml/min. The column effluent was monitored at 340 nm and at 0.005 absorbance units full-scale. Chromatography was performed at room temperature. Following HPLC analysis, the stock preparation of liposome-encapsulated tobramycin was diluted in PBS to administer 300 jig of encapsulated tobramycin in a volume of 100 plA. Liposomeencapsulated PBS was used as a control and was carried through the entire procedure to assess the specificity of the test. The quantifiable limit for tobramycin was 0.5 ,ug/ml. At concentrations from 0.5 to 10 ,ug/ml, the coefficients of variation ranged between 1.2 and 2.9%. Over the same concentrations, the interday coefficients of variation ranged between 2.2 and 3.5%. For seven samples of spiked tobramycin, the standard curve linearity extended over the range 0.5 to 10 ,ug/ml gave a correlation coefficient greater than 0.999.
Tissue preparations. At 0.25, 1, 2, 3, 4, 6, 8, and 16 h after tobramycin instillations, a minimal number of three rats were reanesthetized, and blood was withdrawn by cardiac puncture. The animals were then sacrificed, and the entire lungs and both kidneys were removed aseptically, weighed, and then homogenized in cold sterile PBS (20% [wt/vol]) for 30 s with a Polytron homogenizer (Polytron; Kinematica, Lucerne, Switzerland). The homogenizer was rinsed and flamed between samples. Tobramycin levels in both homogenized tissues and sera were immediately measured as described below.
Antibiotic concentrations in tissues. The concentrations of tobramycin in serum and tissues were measured by a microbiological assay. P. aeruginosa ATCC 25619 (American Type Culture Collection, Rockville, Md.) was grown overnight in Proteose Peptone broth at 37°C, and bacterial suspension was adjusted with PBS to contain an equivalence to a McFarland standard of 0.5 to ensure dense confluent growth on the plates. A total of 12.5 ml of the diluted culture was added to 300 ml of autoclaved molten antibiotic medium 5 (Difco) which had been cooled to 56°C and mixed gently by inversion. The seeded agar was poured onto glass plates (425 by 310 mm) on a horizontal level surface and allowed to harden for 30 min at room temperature. The wells in the plates were made by a puncher device (5-mm diameter) in the agar and filled with 0.025-ml samples and standards, two wells each. The glass plates were covered and incubated overnight (24 h) at 37°C, under 5% CO2. Duplicate zone inhibition diameters were averaged and compared with a series of standards. Standard curves were made with known quantities of free tobramycin added to homogenized lungs or kidneys or sera of normal rats depending on the sample to be assayed. 
RESULTS
One hundred thirty rats weighing 225 to 250 g were used in this study. The animals were divided into the following five groups: group 1 (n = 30), infected animals treated with free tobramycin; group 2 (n = 30), infected animals treated with liposome-encapsulated tobramycin; group 3 (n = 30), uninfected animals treated with free tobramycin; group 4 (n = 30), uninfected animals treated with liposome-encapsulated tobramycin; and group 5 (n = 10), untreated uninfected and infected animals. Uninfected animals received sterile agar beads instead of P. aeruginosa in agar beads. The first four groups were subdivided into seven subgroups corresponding to the time of sacrifice following the antibiotic instillation. In spite of the mortality observed in the different groups following anesthesia and/or infection, the number of animals was sufficient in order to maintain a minimal number of three animals in each subgroup.
A comparison of the concentration of tobramycin in the lungs (micrograms per pair of lungs) after intratracheal instillation of the free and liposome-encapsulated form in uninfected rats is given in Table 1 . Table 1 indicates that significant levels of tobramycin were achieved in the lungs 15 min after instillation of liposome-encapsulated tobramycin and then remained nearly constant over the 16-h period of the study (103.67 ± 18.54 to 69.2 ± 13.0 ,ug per pair of lungs). In contrast, the concentration of the free tobramycin, 15 min after instillation, was 4.5 times lower than that of encapsulated tobramycin and was cleared within 3 h following administration.
In the infected groups (Table 1) , lung antibiotic concentration 15 min after instillation of the free drug was significantly higher (P c 0.05) compared with the liposome-encapsulated tobramycin group (64.02 ± 14.53 to 40.16 ± 2.84 ,ug per pair of lungs). However, no tobramycin was detected 1 h after the administration of its free form. Meanwhile, tobramycin administered in its encapsulated form remained nearly constant in lungs over the 16-h period of the study following its administration.
When we compare the concentrations and the pulmonary retention times of tobramycin in uninfected and infected groups, it clearly shows that pulmonary infection has a significant lowering influence. The mean value of tobramycin level following the administration of the encapsulated drug was 87.00 ,ug per pair of lungs in uninfected rats compared with 32 .84 ,ug per pair of lungs in infected animals, and the pulmonary retention time of the free drug was 2 h in uninfected rats and only 15 min in infected rats (Table 1) .
No antibiotic was found in the kidneys in any of the animal groups. No antibiotic was detected in the serum of animals treated with liposome-encapsulated tobramycin. Nevertheless, traces of tobramycin inferior to the threshold of quantitative sensitivity of our microbiological assay were detected in serum of uninfected groups treated with free tobramycin at 15 min, 1 h, and 2 h after instillations.
Bacterial colony counts performed in lungs of about 30% of infected rats showed that infections were maintained in all animals tested. Regardless of whether free or liposomal tobramycin was given, we observed similar bacterial counts at each time point as shown in Table 2 (30), gentamicin (15) , insulin (26) , and catalase (32) into the lungs of rodents and rabbits. This approach fulfills three therapeutically desirable goals in cases of lower respiratory tract infection: (i) direct targeting of the drug where it is most needed; (ii) ensuring a prolonged residence time of the drug through its slow and sustained release from liposomes; and (iii) the possibility of increasing antibiotic regimens with minimal or complete absence of toxicity.
Taking into consideration the accelerated elimination of antibiotics in CF patients (21) , the poor antibiotic penetration of endobronchial secretions in conventional antibiotic therapy, the need to administer large intravenous doses with risk for nephrotoxic and ototoxic effects (1, 13) , and the characteristics of P. aeruginosa pulmonary infection in CF (18), we hypothesized that in situ administration of encapsulated antibiotics was a promising alternative for the treatment of chronic P. aeruginosa pulmonary infections in CF.
To evaluate the pertinence of our hypothesis, we developed an animal model to compare the pulmonary retention times of free and liposomal tobramycin formulations administered in situ. The possible influence of pulmonary infection on tissue retention of liposome-encapsulated tobramycin was also examined.
Our results show that intratracheal administration of liposome-encapsulated tobramycin compared with that of free tobramycin resulted in a prolonged pulmonary retention time (15 min versus a minimal duration of 960 min) of the active antibiotic within the lungs of infected rats (Table 1) ; the measured antibiotic was still active, since it was detected by a microbiological assay (Table 1 ). The prolonged pulmonary retention time observed for encapsulated tobramycin is consistent with other studies that have demonstrated that liposome encapsulation of drugs markedly increased their residence times in the lungs after intratracheal instillation or aerosolization compared with that of the free drugs (16, 22, 23) .
As a whole, the pulmonary retention time of the encapsulated form of tobramycin in lungs was apparently not shortened by the presence of infection; nevertheless, the infection significantly reduced the quantity of antibiotic detected in lungs. This may be explained in terms of enhanced passage of the antibiotics across the inflamed tissues due to vasodilation and increased vascular permeability, which are often associated with bacterially infected lung tissues (9, 34, 42) . Other factors, such as the inactivation of liberated tobramycin in situ by polymorphonuclear leukocytes, nucleic acids from purulent exudates (10) , and decreased endobrochial pH, might also have played a role in this phenomenon (11) .
In normal animals, it is not clear whether the liposomes are taken up by the lung tissue or whether the vesicles remain in the air spaces. It has been shown that the lipid composition of the carrier vesicle is an important determinant of the interaction of liposomes with cells and the rate of release of the entrapped agent (3, 35, 40) . Recent work has shown that intratracheally instilled liposomes were largely cleared from cell-free bronchoalveolar lavage by 24 h and became associated with lung tissue (23); 16 to 35% of the administered drug was transported to pulmonary tissues within 72 h. Depending on the phospholipids used, extracellular release may play an important role in liposome-mediated drug delivery. Liposomes may also have been engulfed by alveolar macrophages, but the extent of phagocytosis by alveolar macrophages depends on the lipid composition of the liposomes and remains controversial. In a study following the intratracheal injection of the radiolabeled liposome dipalmitoyl phosphatidylcholine in the rabbit lung, it has been shown that >65% of the cell-associated radiolabeled dipalmitoyl phosphatidylcholines were recovered in type II pneumocytes, while the total contribution of alveolar macrophages to the dipalmitoyl phosphatidylcholine overall clearance was approximately 20% (36) .
The very rapid elimination of free tobramycin in the infected rats in comparison with that in uninfected animals may also be explained in the same way as that for the encapsulated form of the drug; moreover, it seems that the residence time of tobramycin in lungs of rats is short, since its half-life has been reported to be 30 to 35 min (27) .
We did not detect tobramycin in kidneys at any time, but when measuring tobramycin in sera, we found traces of this antibiotic in uninfected rats up to 2 h following administration of a single dose (300 ,ug) of free tobramycin. This phenomenon was not observed with the liposomal forms of tobramycin and may be an indication of their reduced systemic absorption and toxicity, which were well demonstrated in another study (15 
